ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Palmitic Acid Promotes Antiviral Innate Immunity via ZDHHC20-Mediated CMPK2 Palmitoylation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
While immunometabolic crosstalk is critical for antiviral defence, the regulation of this process, particularly through post-translational modifications, remains incompletely understood. How specific metabolites and associated modifications orchestrate antiviral immunity remains unclear. By screening a metabolic chemical library, we identify palmitic acid (PA) as an activator of antiviral immunity in macrophages. PA induces UMP-CMP kinase 2 (CMPK2) palmitoylation, maintaining its mitochondrial localization. CMPK2 is vital for the production of 3'-deoxy-3',4',-didehydrocytidine triphosphate (ddhCTP) and the stabilization of mitochondrial antiviral signaling protein (MAVS), both of which are crucial for defence against RNA viruses. Cmpk2 deficiency impairs IFN-I production and increases viral replication. Furthermore, the palmitoyl transferase ZDHHC20 catalyzes CMPK2 palmitoylation at cysteines 137 and 153, which are depalmitoylated by the thioesterase PPT1. PPT1 deficiency restores CMPK2 palmitoylation and antiviral immunity. Both a palm oil-rich diet and the in vivo administration of the PPT1 inhibitor DC661 increase IFN-I production. Therefore, the PA-ZDHHC20-CMPK2-PPT1 axis enhances the antiviral response, indicating that targeting PPT1 has the potential to treat RNA virus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.